{"disease":{"id":"lung-cancer-recurrent","name":"lung cancer recurrent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03533127","title":"A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":648,"lead_sponsor_name":"Luye Pharma Group Ltd.","has_results":false},{"nct_id":"NCT04623775","title":"A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":468,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT01040312","title":"An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT04986670","title":"NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":299,"lead_sponsor_name":"Tufts University","has_results":false},{"nct_id":"NCT03235765","title":"Cancer Panel From Blood of Lung Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02729298","title":"First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT06681220","title":"Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":166,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT03721133","title":"Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT02922764","title":"A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Inspirna, Inc.","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT05110118","title":"Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Shandong Boan Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT06648200","title":"Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT06848426","title":"Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jiangxi Provincial People's Hopital","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06538012","title":"TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06525246","title":"Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03994744","title":"Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT06007937","title":"A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03602079","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT03823118","title":"S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Taizhou Hospital","has_results":false},{"nct_id":"NCT04965090","title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02423343","title":"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT07509034","title":"Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06258642","title":"Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC","phase":"NA","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03262454","title":"Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT01649947","title":"Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT06728852","title":"Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Li-kun Chen","has_results":false},{"nct_id":"NCT05842018","title":"Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04340882","title":"Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01345851","title":"Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":29,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03322072","title":"Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating","phase":"NA","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"CancerCare Manitoba","has_results":false},{"nct_id":"NCT07355205","title":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06979661","title":"Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT03076164","title":"A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT01471964","title":"Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT05617313","title":"Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Jeffrey Clarke","has_results":false},{"nct_id":"NCT03445000","title":"ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT04610658","title":"Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01706432","title":"Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT05027867","title":"KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04878952","title":"Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"NRG Oncology","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}